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Aim To determine the appropriate timing of cardiac tro-
ponin T (cTnT) measurement for the early triage of pulmo-
nary embolism (PE) patients.
Methods In this single-center prospective study, PE was 
confirmed in all patients using computed tomography. 
104 consecutive patients were divided into three groups 
(high-risk, intermediate, and low-risk) based on their he-
modynamic status and echocardiographic signs of right 
ventricular dysfunction. cTnT levels were measured on ad-
mission and then after 6, 24, 48, and 72 hours with thresh-
old values greater than 0.1 ng/mL.
Results Intermediate-risk PE patients had higher cTnT lev-
els than low-risk patients already in the first measurement 
(P = 0.037). Elevated cTnT levels significantly correlated 
with disease severity after 6 hours (intermediate vs low risk 
patients, P = 0.016, all three groups, P = 0.009).
Conclusion In hemodynamically stable patients, increased 
cTnT level on admission differentiated intermediate from 
low-risk patients and could be used as an important ele-
ment for the appropriate triage of patients.
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Pulmonary embolism (PE) still remains one of the most fre-
quent causes of death among patients in emergency set-
tings. Early identification of high-risk patients and optimal 
treatment administration is often difficult due to the clini-
cal variability of the disease. Several risk-stratification tools 
have been recently proposed based on echocardiography, 
biomarkers (troponins and natriuretic peptides), and com-
puted tomography (1). Right ventricular dysfunction (RVD) 
is a central hemodynamic event in PE patients, and repre-
sents an independent prognostic factor of adverse events. 
Multiple clinical studies have convincingly shown that RVD 
in hypotensive and normotensive PE patients directly af-
fects early mortality (2). A meta-analysis by ten Wolde et 
al clearly indicates that RVD is associated with a two times 
higher risk of PE related mortality (3). According to the cur-
rent European Society of Cardiology (ESC) guidelines, ther-
apy should be tailored to the estimated risk of death due 
to acute pulmonary embolism (4). The guidelines divide PE 
patients into three groups: high-risk (PE related mortality 
risk >15%), intermediate (PE related mortality risk 3%-15%), 
and low-risk patients (PE related mortality risk <1%) based 
on the presence of right ventricular dysfunction (measured 
by echocardiography, computed tomography, and natri-
uretic peptides) or injury (troponins). Higher risk patients 
should be treated with thrombolytic therapy in an inten-
sive care unit (ICU), while non-high-risk patients should be 
additionally stratified and treated either in an ICU (interme-
diate-risk) or clinical ward (low-risk patients).
Laboratory evaluations of acute right ventricular injury in 
PE patients have been extensively performed over the past 
few years, with a special emphasis on the prognostic value 
of serum troponins due to their wide use in the routine 
evaluation of patients with chest pain. Elevated levels of 
serum troponin are found in approximately 30%-50% of 
patients with pulmonary embolism (5,6). Despite low diag-
nostic accuracy, the prognostic value of elevated troponin 
levels in PE patients is well documented, and according to 
one study, is associated with a 3.5 times higher risk of total 
mortality during 3 months follow-up (4,7). In PE patients, 
the increase in serum troponin is usually moderate and its 
retention in plasma is shorter (up to 3 days) than in pa-
tients with acute coronary syndromes (8).
In an emergency department setting, patients with estab-
lished PE should be properly stratified and consequently ad-
mitted either to an ICU or medical ward according to the 
presence of RVD or right ventricular injury. However, the 
optimal timing for troponin measurement has not been 
established due to methodological differences in clin-
ical trials where different times for troponin sampling have 
been used (4) It is not clear whether the initial measurement 
of cardiac troponin in emergency department is enough for 
early clinical triage, or if subsequent control measurements 
are required in order to distinguish patients who need ICU 
or clinical ward treatment and surveillance. Thus, the aim of 
the present study is to investigate the appropriate timing of 
cardiac troponin T (cTnT) measurement for the early triage 
and follow up of pulmonary embolism patients.
PatIeNtS aND MetHoDS
This single-center prospective longitudinal observational 
study of a cohort of PE patients was conducted from Sep-
tember 2009 to November 2011 in the medical intensive 
care unit (ICU) at the “Sestre Milosrdnice” University Hospi-
tal Center in Zagreb, Croatia. The study population includ-
ed 109 consecutive patients. In all patients the diagnosis of 
PE was confirmed by contrast enhanced spiral computed 
tomography during the first 3 hours after first admission 
to the emergency department. After ICU admission, com-
plete data on baseline clinical, hemodynamic, and labora-
tory parameters were obtained using a standardized ques-
tionnaire by an intensive care specialist. All patients gave 
their informed consent. “Sestre Milosrdnice” University Hos-
pital Center committee on human research approved the 
study protocol as a non-interventional study. Patients were 
excluded from analysis if they met at least one of the fol-
lowing criteria: (i) denial of preliminary consent or with-
drawal of previously given consent for participation in the 
study; (ii) severe renal insufficiency or failure, defined as 
an estimated glomerular filtration rate (eGFR) of <30 mL/
min/1.73m2 on admission; and (iii) left ventricular systolic 
dysfunction (ejection fraction <40%) or severe mitral valve 
disease as a potential cause of pulmonary hypertension 
and right heart disease. The study protocol strongly recom-
mended a transthoracic echocardiogram within 24 hours 
of PE diagnosis. Right ventricular dysfunction was defined 
by the presence of at least one of following criteria: dilata-
tion of the right ventricle (an end-diastolic diameter >30 
mm from the parasternal view or a right/left ventricle di-
ameter ratio >1.0 from the subcostal or apical view), septal 
systolic flattening, right ventricular free wall hypokinesis, or 
a tricuspid regurgitation jet >2.7 m/s.
Patients were, according to their baseline short-term mor-
tality risk, stratified into three severity groups: patients with 
high-risk (hemodynamically unstable patients defined as 
having a systolic blood pressure of <90 mm Hg, or a drop 
in systolic blood pressure of ≥40 mm Hg from baseline for 
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a period >15 minutes); intermediate-risk (hemodynamical-
ly stable patients with a systolic blood pressure of >90 mm 
Hg and echocardiographic signs of RVD); and low-risk (he-
modynamically stable patients with a systolic blood pres-
sure of >90 mm Hg and without echocardiographic signs 
of RVD). Patients were followed up until hospital discharge 
or death (Figure 1).
Blood sampling for cTnT was done similarly to the protocol 
used for acute coronary syndromes as recommended by 
the European Society of Cardiology guidelines (9,10). The 
study protocol recommended cTnT level measurement 
from blood samples obtained initially in emergency de-
partment and then after 6 hours in order to rule out ini-
tial “false negative” findings. Additional measurements, in 
accordance with the study protocol, were obtained after 
24, 48, and 72 hours after admission in order to determine 
peak levels of the marker. cTnT was determined in serum 
by highly sensitive and specific electrochemiluminescent 
immunoassay (cTnT, Cat. No. 05092728) using the analyzer 
Elecsys 2010. Reagents, calibrators, and control samples, as 
well as the analyzer were all from the same manufacturer 
FIgure 1. Study protocol. Pe – pulmonary embolism; Ct - computed tomography; ctnt – cardiac troponin t; egFr – estimated glom-
erular filtration rate; LV eF – left ventricular ejection fraction; rVD – right ventricular dysfunction.
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(F. Hoffmann-La Roche Ltd, Basel, Switzerland). The lower 
limit of detection for cTnT was 0.01 ng/mL. Based on the 
reference values of our laboratory, plasma concentrations 
of cTnT>0.1 ng/mL were considered to indicate myocardial 
injury and were used as the threshold value.
The eGFR was estimated using the Modification of Diet 
in Renal Disease (MDRD) study equation; renal insuffi-
ciency/chronic kidney disease was defined as GFR 30-60 
mL/min/1.73 m2 body-surface area, and severe renal in-
sufficiency or kidney failure as GFR<30 mL/min/1.73 m2 
(11). Serum creatinine was measured by the Jaffe method 
(Modular P, Roche Diagnostic, Mannheim, Germany) (12).
Statistical analysis
To determine the sample size, an initial power analysis for 
χ2 test was performed with the following parameters: esti-
mated effect size w = 0.4, α significance level 0.05, statistical 
power of 0.95, and 3 investigated groups (high risk, inter-
mediate risk, and low risk PE). Sample size needed to meet 
these demands was 97. In total, 104 participants were in-
cluded to account for possible drop outs or missing data.
Data were analyzed with STASTICA software, version 
10.0 (StatSoft, Inc. Tulsa, OK, USA). Continuous variables 
normality of distribution was assessed with Kolmogov-
Smirnov test. Continuous variables are presented as the 
mean ± standard deviation (SD) or median with inter-
quartile range (IQR) according to data distribution. Box-
and-Whisker plot represents medians with corresponding 
interquartile ranges, minimal and maximal values (exclud-
ing outliers). Data for variables assessed on nominal or or-
dinal scale were presented in contingency tables and ana-
lyzed by χ2 test (or Fisher exact test where appropriate – 2 
by 2 table). The Mann-Whitney U test was used to compare 
taBLe 1. Baseline characteristics of 104 patients with acute pulmonary embolism (Pe)
group
high risk Pe 
(N = 33)
intermediate risk Pe 
(N = 51)
low risk Pe 
(N = 20) P* P†
Female/male sex: n (%) 22 (66.7) 34 (66.7) 10 (50.0) 0.193 0.380
11 (33.3) 17 (33.3) 10 (50.0)
reported symptom onset <12h: n (%) 17 (51.5) 13 (25.5)  3 (15.0) 0.341 0.009
reported symptom onset >12h: n (%) 16 (48.5) 38 (74.5) 17 (75.0)
Symptoms: n (%)
Dyspnea 32 (97.0) 48 (94.1) 15 (75.0) 0.022 0.014
Syncope 19 (57.6)  2 (3.9)  0 (0.0) 0.396 <0.001
Chest pain 22 (66.7) 30 (58.8)  6 (30.0) 0.029 0.028
Cough 18 (54.5) 22 (43.1)  8 (40.0) 0.81 0.49
Tachycardia 22 (66.7) 32 (62.7)  4 (20.0) 0.001 0.002
Malignant tumor  8 (24.2) 18 (35.3)  6 (30.0) 0.671 0.561
Previous history of deep vein thrombosis or PE  5 (15.2)  6 (11.8)  4 (20.0) 0.37 0.667
Immobilization within 14 d 14 (42.4) 18 (35.3)  3 (15.0) 0.092 0.116
Positive family history  1 (3.0)  1 (2.0)  1 (5.0) 0.486 0.788
Adiposity  8 (24.2) 17 (33.3)  6 (30.0) 0.787 0.673
Death: n (%) 11 (30.0)  2 (3.9)  0 (0.0) 0.369 <0.001
Cardiac troponin t > 0.1 ng/mL: 0h, n (%) 11 (33.3) 14 (27.5)  1 (5.0) 0.037 0.059
Cardiac troponin t > 0.1 ng/mL: 6h, n (%) 11 (33.3) 14 (27.5)  0 (0.0) 0.009 0.016
Cardiac troponin t > 0.1 ng/mL: 24h, n (%)  6 (18.2)  8 (15.7)  0 (0.0) 0.6 0.138
Cardiac troponin t > 0.1 ng/mL: 48h, n (%)  5 (15.2)  4 (7.8)  0 (0.0) 0.197 0.157
Cardiac troponin t > 0.1 ng/mL: 72h, n (%)  2 (6.1)  4 (7.8)  0 (0.0) 0.197 0.442
age (years): median (IQr) 74.0 (64.0-79.0) 71.0 (62.0-78.0) 70.0 (56.0-75.5) 0.561§ 0.459‡
Body mass index (kg/m2): median (IQr) 27.0 (25.0-30.0) 27.0 (24.0-31.0) 27.5 (25.0-30.0) 0.898§ 0.930‡
Creatinine: median (IQr) 95.0 (84.0-106.0) 105.0 (95.0-125.0) 97.0 (72.5-104.0) 0.015§ 0.005‡
estimated glomerular filtration rate: median (IQr) 57.0 (49.0-71.0) 52.0 (42.0-64.0) 69.5 (53.5-77.5) 0.007§ 0.012‡
*Differences between low and intermediate risk for Pe.
†Differences between all three risk groups for Pe.
‡Kruskal-Wallis test; IQr – interquartile range.
§Mann-Whitney u test; IQr – interquartile range.
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differences in continuous variables between two groups 
(cTnT<or >0.1 ng/mL) and Kruskal-Wallis test was used for 
comparisons between three severity groups (high, inter-
mediate, and low-risk PE). Differences were considered sig-
nificant if the P value was <0.05.
reSuLtS
A total of 109 consecutive patients were admitted to the 
“Sestre Milosrdnice” University Hospital Center with con-
firmed diagnosis of PE by computer tomography. Five pa-
tients (4.0%) were excluded from further analysis due to (i) 
renal failure with a GFR of <30 mL/min/1.73 m2 (n = 1), or 
(ii) left ventricular dysfunction with EF<40% (n = 4). None 
of the patients withdrew his/her consent. Thus, the final 
study population comprised 104 patients with acute PE. 
The patients had a mean age of 68.7 ± 13.4 (range, 25-
89 years) and there was a female predominance (63.5%). 
There were 13 (12.5%) in-hospital deaths on the first day of 
hospitalization, and most of these were in the group with 
high-risk PE (11 patients). There were 33 (31.7%) patients 
in the high-risk, 51 (49.1%) in the intermediate-risk, and 20 
(19.2%) in the low-risk group (Table 1). All patients were 
treated with low molecular weight heparin (enoxaparin 
1 mg/kg subcutaneously every 12 hours), and no one re-
ceived thrombolytics.
Most frequent clinical characteristics of the patients were 
dyspnea, chest pain, and tachycardia (Table 1). When com-
pared with hemodynamically stable patients, syncope and 
shorter duration of symptoms (less than 12 hours) were 
more frequent in high-risk patients. Also eGFR<60 mL/
min/1.73 m2 was observed more frequently in patients with 
high- and intermediate-risk PE than in low-risk PE patients.
Positive values of cTnT were detected in 29 of the 104 inves-
tigated patients (27.80%), with cTnT value already positive 
in 26 patients in the emergency department. Three of the 
initially positive cTnT patients in the high-risk group died 
and 3 initially cTnT negative patients reached cTnT>0.1 ng/
mL 6 hours after admission. There were no new positives 
in the intermediate and low risk groups. Troponine posi-
taBLe 2. Positive and negative findings of cardiac troponin t (ctnt) in 104 patients with acute pulmonary embolism (Pe)
ctnt>0.1 ng/mL
negative N = 75 positive N = 29 P*
High risk Pe: n (%) 20 (26.7) 13 (44.8) 0.024
Intermediate risk Pe: n (%) 36 (48.0) 15 (51.7)
Low risk Pe: n (%) 19 (25.3)  1 (3.4)
Female: n (%) 45 (60.0) 21 (72.4) 0.238
Male: n (%) 30 (40.0)  8 (27.6)
reported symptom onset >12 h: n (%) 52 (69.3) 19 (65.5) 0.708
reported symptom onset <12 h: n (%) 23 (30.7) 10 (34.3)
Symptoms: n (%)
Dyspnoea 67 (89.3) 28 (96.6) 0.240
Syncope 13 (17.3)  8 (27.6) 0.243
Chest pain 38 (50.7) 20 (69.0) 0.092
Cough 38 (50.7) 10 (34.5) 0.138
Tachycardia 37 (49.3) 21 (72.4) 0.034
Malignant tumor 26 (34.7)  6 (20.7) 0.166
Previous history of deep vein thrombosis or PE 12 (16.0)  3 (10.3) 0.462
Immobilization within 14 d 27 (36.0)  8 (27.6) 0.415
Family history  2 (2.7)  1 (3.4) 0.831
Adiposity 23 (30.7)  8 (27.6) 0.758
rVD (echo positive): n (%) 58 (85.3) 29 (100.0) 0.029
Death: n (%) 10 (13.3)  3 (10.3) 0.679
age (years): median (IQr)* 75.0 (64.0-78.0) 67.0 (60.5-80.5) 0.446
Body mass index (kg/m2): median (IQr)* 27.0 (24.0-30.0) 27.0 (24.5-30.0) 0.791
Creatinine: median (IQr)* 99.0 (88.0-112.0) 99.0 (90.5-116.5) 0.960
estimated glomerular filtration rate: median (IQr) 59.0 (49.0-71.0) 53.0 (44.5-69.5) 0.374
*Mann-Whitney u test; IQr – interquartile range; rVD – right ventricular dysfunction.
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tive patients were more frequently tachycardic (P = 0.034) 
and had right ventricular dysfunction (P = 0.029) (Table 2). 
Although the proportion of cTnT positive patients in high-
risk group reached borderline significance (P = 0.059), this 
was observed in the first control measurement after 6 
hours (P = 0.016). Control measurements of cTnT at 24, 48, 
and 72 hours after admission revealed no significant corre-
lation with disease severity.
Fifteen (21.1%) out of 71 hemodynamically stable patients 
(intermediate and low risk group) had cTnT levels above 
0.1 ng/mL. A significant proportion of cTnT positive pa-
tients was found in the intermediate-risk group in the first 
emergency department measurement (P = 0.037). The pro-
portion remained significant in the first control measure-
ment 6 hours after admission (P = 0.009). This was not ob-
served in subsequent control measurements 24, 48, and 72 
hours after admission.
On average, the first cTnT value was already positive on ad-
mission. cTnT peak occurred on average 6 hours after ad-
mission, and levels subsequently decreased (Figure 2).
DISCuSSIoN
The present study showed that when assessing PE pa-
tients in the emergency department two consecutive as-
sessments of cTnT at an interval of 6 hours allowed for the 
identification of PE patients who required ICU admission 
and aggressive treatment. Pulmonary embolism is a medi-
cal emergency with a high mortality rate that in untreated 
patients reaches 30%. This is mainly due to repeated throm-
boembolism a few hours following the initial event (13,14). 
Early detection and accurate diagnosis of high-risk patients 
is therefore of crucial importance for an appropriate treat-
ment strategy and mortality reduction. Hemodynamic sta-
tus at the time of admission is the most important prognos-
tic factor of short-term mortality (15). High-risk pulmonary 
embolism or hemodynamically unstable pulmonary embo-
lism is usually defined by the presence of circulatory shock 
and a mortality rate above 15%. On the other hand, a vast 
majority of patients are hemodynamically stable and can 
be considered to have non-high-risk pulmonary embolism. 
The mortality rate for this group ranges from 1%-15%. This 
large range reflects a wide spectrum of severity, ranging 
from trivial pulmonary embolism to pulmonary embolism 
with compensated shock that could deteriorate at any mo-
ment. In order to identify hemodynamically stable patients 
with increased risk of PE related complication, several risk-
stratification tools were proposed based on clinical scores, 
imaging tools (CT and echocardiography), and biomarkers 
(troponins and natriuretic peptides) (16,17).
Elevation of cTnTs during acute PE occurs in 13%-50% of 
patients (18,19). cTnT is a highly sensitive and specific mark-
er of myocardial necrosis and is the current gold standard 
biomarker for diagnosing myocardial infarction (20). Dur-
ing the acute phase of PE, the sudden rise in pulmonary 
vascular resistance secondary to pulmonary thrombi can 
lead to acute pressure overload of the right ventricle. Cou-
pled with hypoxia and right coronary hypoperfusion due 
to systemic hypotension, there ensues myocardial isch-
emia/necrosis. In the last decade, several smaller studies 
have shown that elevation of cTnTs during acute PE is as-
sociated with increased in-hospital and short-term mortal-
ity (21,22). A meta-analysis of 20 clinical trials showed that 
elevated levels of troponin in patients with PE were associ-
ated with an increased risk of early mortality, which applies 
both to hemodynamically unstable and stable patients 
(23). Thrombolytic treatment, usually performed in cases of 
severe PE with hemodynamic instability with right ventric-
ular dysfunction and/or injury, may offer a life-saving ther-
apy. Moreover, in a multicentric randomized trial of throm-
bolytics in normotensive PE patients (PEITHO trial), positive 
troponin was one of the main criteria for patient selection 
(24). On the other hand, in low-risk patients thrombolytic 
therapy is contraindicated, and anticoagulant therapy can 
be administered in hospital wards only. Furthermore, ac-
cording to recent studies, some low-risk PE patients could 
be treated as outpatients (25,26). Since the availability of a 
FIgure 2. Cardiac troponin t kinetics in all investigated 
patients. Itis positive in 29 (27.8%) patients with peak levels 
observed at 6h.
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cardiac ultrasound on a round-the-clock basis can be a sig-
nificant problem in some hospitals, and for some patients 
an echocardiographic exam can be difficult to perform in 
emergency settings, cTnTs could play an important role in 
the early clinical triage of PE patients.
Despite having good prognostic value, the appropriate 
timing for troponin measurement in PE patients is still un-
clear. The only study dealing with this issue included 200 
hemodynamically stable PE patients and measured cardi-
ac troponin I (cTnI) at admission and then every 8 hours 
following admission over a three-day period (27). They 
found that 15% of patients at the time of admission were 
misclassified as cTnI negative. The highest cTnI level was 
consistently reached 8 hours after initial presentation. The 
authors concluded that the first measurement of cTnI was 
a “false negative” because of a delay in the release of tro-
ponins after right heart injury. Two consecutive assess-
ments of cTnI at an 8-hour interval allowed for the correct 
risk stratification of patients suffering from PE and patients 
with increased cTnI on admission, and a further blood sam-
ple for cTnI assessment was deemed unnecessary (27). Our 
study analyzed cTnT and suggested that initial “false nega-
tive” cTnT levels occurred only in hemodynamically unsta-
ble patients with shorter symptom durations. In unstable 
patients who survived the initial event, cTnT reached posi-
tive levels after 6 hours following admission. On the other 
hand, in hemodynamically stable patients with intermedi-
ate-risk PE, cTnT levels were found positive at the time of 
admission and remained positive for the next 6 hours. Fur-
thermore, our data showed that, unlike patients with acute 
coronary syndromes, the most informative levels of cTnT 
were reached 6 hours after admission, with decreased val-
ues in subsequent measurements, and without the need 
for further blood sampling for cTnT measurement.
Although the final number of included participants com-
plied with the sample calculation in power analysis, we see 
a potential drawback in different sizes of three analyzed 
groups. In our opinion, any future investigations should in-
corporate a larger and more balanced sample of patients, 
ideally using a multi-center design. This study was not de-
signed to evaluate differences in mortality, still it might 
have some important clinical implications regarding the 
early triage of PE patients.
In conclusion, when assessing PE patients in the emergen-
cy department, two consecutive assessments of cTnT at a 
6-hour interval should allow for the identification of PE pa-
tients who require aggressive ICU treatment and surveil-
lance. In hemodynamically stable patients, an increased 
cTnT level on admission distinguishes intermediate from 
low-risk patients and could be used for the appropriate tri-
age of patients.
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